Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Aug. 14, 2025 /CNW/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dynamic is setting the stage for a "flight to quality" among investors, who are now more than ever looking for innovative leaders with strong pipelines and clear paths to regulatory execution, a key milestone that can separate a promising biotech from a potential breakthrough like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), ProPhase Labs, Inc. (NASDAQ:PRPH), IO Biotech, Inc. (NASDAQ:IOBT), Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), and PDS Biotechnology Corporation (NASDAQ:PDSB).